Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories Limited, NDA 209481.

According to IQVIA™ sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), adding another quality product to our institutional portfolio."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1540.05 as compared to the previous close of Rs. 1520.75. The total number of shares traded during the day was 17502 in over 2999 trades.

The stock hit an intraday high of Rs. 1546.65 and intraday low of 1502.50. The net turnover during the day was Rs. 26795480.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USA VancomycinHydrochloride Injection